secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001193125-26-064040
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics stockholders approve reverse stock split and warrant issuances
-----------------------------------------------------------------------------

- Reverse stock split approved at ratio between 1:5 and 1:30, with board discretion; 53.6M votes for, 1.3M against.
- Issuance of up to 12.1M shares upon exercise of warrants from Nov 18, 2025 SPA approved (47.9M for, 1.2M against).
- Issuance of up to 4.8M shares upon exercise of warrants from Nov 24, 2025 SPA and related engagement letter approved.
- Issuance of up to 5.6M shares upon exercise of warrants from Dec 14, 2025 SPA and related engagement letter approved.
- Adjournment proposal also passed; all five proposals approved at Feb 20, 2026 special meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526064040/0001193125-26-064040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526064040/fblg-20260220.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-064040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer